Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. More Details
Flawless balance sheet with acceptable track record.
Share Price & News
How has Haw Par's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: H02 is less volatile than 75% of SG stocks over the past 3 months, typically moving +/- 2% a week.
Volatility Over Time: H02's weekly volatility (2%) has been stable over the past year.
7 Day Return
1 Year Return
Return vs Industry: H02 underperformed the SG Pharmaceuticals industry which returned -7.3% over the past year.
Return vs Market: H02 underperformed the SG Market which returned -14.3% over the past year.
Long-Term Price Volatility Vs. Market
How volatile is Haw Par's share price compared to the market and industry in the last 5 years?
Simply Wall St News
1 week ago | Simply Wall StShareholders Of Haw Par (SGX:H02) Must Be Happy With Their 50% Return
1 month ago | Simply Wall StOur Take On Haw Par's (SGX:H02) CEO Salary
1 month ago | Simply Wall StWhat Kind Of Investors Own Most Of Haw Par Corporation Limited (SGX:H02)?
Is Haw Par undervalued compared to its fair value and its price relative to the market?
Price to Earnings (PE) ratio
Share Price vs. Fair Value
Below Fair Value: H02 (SGD10.4) is trading above our estimate of fair value (SGD6.24)
Significantly Below Fair Value: H02 is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: H02 is good value based on its PE Ratio (14.3x) compared to the XA Pharmaceuticals industry average (25.6x).
PE vs Market: H02 is poor value based on its PE Ratio (14.3x) compared to the SG market (14x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate H02's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: H02 is good value based on its PB Ratio (0.9x) compared to the SG Pharmaceuticals industry average (1.5x).
How is Haw Par forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Pharmaceuticals & Biotech industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Haw Par has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine Haw Par's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
- Haw Par competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Pharmaceuticals & Biotech industry.
How has Haw Par performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: H02 has high quality earnings.
Growing Profit Margin: H02's current net profit margins (88.6%) are higher than last year (74%).
Past Earnings Growth Analysis
Earnings Trend: H02's earnings have grown by 4% per year over the past 5 years.
Accelerating Growth: H02's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: H02 had negative earnings growth (-15.5%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (12.9%).
Return on Equity
High ROE: H02's Return on Equity (6.1%) is considered low.
How is Haw Par's financial position?
Financial Position Analysis
Short Term Liabilities: H02's short term assets (SGD634.6M) exceed its short term liabilities (SGD107.2M).
Long Term Liabilities: H02's short term assets (SGD634.6M) exceed its long term liabilities (SGD820.0K).
Debt to Equity History and Analysis
Debt Level: H02 is debt free.
Reducing Debt: H02 has no debt compared to 5 years ago when its debt to equity ratio was 2%.
Debt Coverage: H02 has no debt, therefore it does not need to be covered by operating cash flow.
Interest Coverage: H02 has no debt, therefore coverage of interest payments is not a concern.
What is Haw Par current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: H02's dividend (2.88%) is higher than the bottom 25% of dividend payers in the SG market (2.41%).
High Dividend: H02's dividend (2.88%) is low compared to the top 25% of dividend payers in the SG market (5.19%).
Stability and Growth of Payments
Stable Dividend: H02's dividend payments have been volatile in the past 10 years.
Growing Dividend: H02's dividend payments have increased over the past 10 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (41.3%), H02's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Ee Lim Wee (59 yo)
Mr. Ee Lim Wee serves as Deputy Chairman at UOL Group Limited. Mr. Wee has been the Chief Executive Officer and President of Haw Par Corporation Limited since April 1, 2003. Mr. Wee has been an Acting Pres...
CEO Compensation Analysis
Compensation vs Market: Ee Lim's total compensation ($USD1.84M) is above average for companies of similar size in the SG market ($USD1.06M).
Compensation vs Earnings: Ee Lim's compensation has been consistent with company performance over the past year.
|CEO, President & Executive Non-Independent Director||17.17yrs||S$2.47m||0.20% |
|Group Financial Controller||no data||no data||no data|
|Legal Counsel & Company Secretary||1.75yrs||no data||no data|
|Manager of Corporate Communications||no data||no data||no data|
|Human Resource Director||3.92yrs||no data||no data|
|Regional General Manager of Underwater World Singapore Pte Ltd & Haw Par Leisure Pte Ltd||18.92yrs||no data||no data|
Experienced Management: H02's management team is seasoned and experienced (10.5 years average tenure).
|CEO, President & Executive Non-Independent Director||17.17yrs||S$2.47m||0.20% |
|Non-Executive Independent Director||6.33yrs||S$55.00k||no data|
|Non-Executive & Non-Independent Chairman||42.92yrs||S$100.00k||0.55% |
|Non-Executive & Independent Director||34.17yrs||S$50.00k||no data|
|Non-Executive Independent Director||25yrs||S$50.00k||no data|
|Non-Executive Deputy Chairman||4.83yrs||S$59.00k||0.0063% |
|Non-Executive Independent Director||9.58yrs||S$60.00k||no data|
|Non-Executive Independent Director||43.92yrs||S$65.00k||0.043% |
|Non-Executive & Independent Director||0.50yr||no data||no data|
|Non-Executive Independent Director||9.58yrs||S$65.00k||no data|
|Non-Executive & Independent Director||1.83yrs||S$43.00k||no data|
Experienced Board: H02's board of directors are considered experienced (9.6 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Haw Par Corporation Limited's company bio, employee growth, exchange listings and data sources
- Name: Haw Par Corporation Limited
- Ticker: H02
- Exchange: SGX
- Founded: 1969
- Industry: Pharmaceuticals
- Sector: Pharmaceuticals & Biotech
- Market Cap: S$2.296b
- Shares outstanding: 221.19m
- Website: https://www.hawpar.com
Number of Employees
- Haw Par Corporation Limited
- No. 03-03 Haw Par Technocentre
- 401 Commonwealth Drive
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|HAWP.F||OTCPK (Pink Sheets LLC)||Yes||Ordinary Shares||US||USD||Jan 1992|
|H02||SGX (Singapore Exchange)||Yes||Ordinary Shares||SG||SGD||Jan 1992|
|HAWP.Y||OTCPK (Pink Sheets LLC)||UNSPONSORD ADR||US||USD||Oct 2011|
Haw Par Corporation Limited, together with its subsidiaries, manufactures, markets, and trades in healthcare products in Singapore, ASEAN countries, other Asian countries, and internationally. The company ...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/12/03 11:10|
|End of Day Share Price||2020/12/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.